Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Investigación de la quimioterapia vesical en lugar de la cirugía para el cáncer de vejiga de bajo riesgo (CALIBER)

4 de noviembre de 2026 actualizado por: Institute of Cancer Research, United Kingdom

CALIBER: un estudio de viabilidad aleatorizado de fase II de quimiorresección y tratamiento quirúrgico en el cáncer de vejiga sin invasión muscular de bajo riesgo

Patients diagnosed with low risk non-muscle invasive bladder cancer (NMIBC) are at risk of frequent low grade recurrence, which usually necessitates surgical intervention under general anaesthetic. This multicentre study aims to establish the short term efficacy of chemoresection using chemotherapy within the bladder for the treatment of NMIBC.

Should the levels of complete response following chemoresection meet predefined criteria, a larger phase III trial would be developed to assess longer term disease related endpoints, with the aim of standardising management of recurrent low risk NMIBC and potentially removing the need for over a thousand patients each year to undergo surgery.

Descripción general del estudio

Estado

Terminado

Condiciones

Descripción detallada

CALIBER is a two stage phase II, multicentre, randomised controlled trial (RCT). A control group has been included to provide prospective data about surgical management and outcomes and assess feasibility of recruitment to a randomised study.

Stage 1: 80 patients will be recruited with treatment allocated 2:1 by randomisation between chemoresection and surgical management.

Stage 2: If the stop/go activity criteria at the end of stage 1 indicate that recruitment should continue, 9 additional participants will be recruited, all of whom will receive chemoresection.

Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg Mitomycin C (MMC) as outpatients. This treatment will be delivered via catheter under local anaesthetic.

Patients assigned to the surgical management group will receive the standard surgical management in use at their hospital for treatment of recurrence which may include a single post-operative installation of 40mg MMC within 24 hours.

All participants will be followed up at 3 weeks from the start of treatment (ie at time of final MMC instillation for chemoresection group) and each will receive a cystoscopy three months from the end of treatment to assess response, in accordance with European Association of Urology (EAU) guidelines.

Subsequent cystoscopic follow up will take place 12 months after treatment if recurrence-free at 3 months and then annually.

Tipo de estudio

Intervencionista

Inscripción (Actual)

82

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • London, Reino Unido, NW1 2BU
        • University College Hospital
      • Manchester, Reino Unido, M23 9LT
        • Wythenshawe Hospital
      • Manchester, Reino Unido, M20 2LR
        • Withington Hospital
    • Cheshire
      • Macclesfield, Cheshire, Reino Unido, SK10 3BL
        • Macclesfield District General Hospital
    • Cleveland
      • Middlesbrough, Cleveland, Reino Unido, TS4 3BW
        • James Cook University Hospital
    • Cumbria
      • Whitehaven, Cumbria, Reino Unido, CA28 8JG
        • West Cumberland Hospital
    • Devon
      • Exeter, Devon, Reino Unido, EX2 5DW
        • Royal Devon and Exeter Hospital
      • Plymouth, Devon, Reino Unido, PL6 8DH
        • Derriford Hospital
    • Dorset
      • Bournemouth, Dorset, Reino Unido, BH7 7DW
        • Royal Bournemouth Hospital
      • Dorchester, Dorset, Reino Unido, DT1 2JY
        • Dorset County Hospital
    • England
      • Carlisle, England, Reino Unido, CA2 7HY
        • Cumberland Infirmary
    • Essex
      • Chelmsford, Essex, Reino Unido, CM1 5ET
        • Broomfield Hospital
      • Harlow, Essex, Reino Unido, CM20 1QX
        • Princess Alexandra Hospital
    • Gloucestershire
      • Cheltenham, Gloucestershire, Reino Unido, GL53 7AN
        • Cheltenham General Hospital
      • Gloucester, Gloucestershire, Reino Unido, GL1 3NN
        • Gloucestershire Royal Hospital
    • Greater Manchester
      • Manchester, Greater Manchester, Reino Unido, OL1 2JH
        • Royal Oldham Hospital
    • Hampshire
      • Basingstoke, Hampshire, Reino Unido, RG24 9NA
        • Basingstoke and North Hampshire Hospital
      • Southampton, Hampshire, Reino Unido, SO16 6YD
        • Southampton General Hospital
    • Herefordshire
      • Hereford, Herefordshire, Reino Unido, HR1 2ER
        • Hereford County Hospital
    • Kent
      • Dartford, Kent, Reino Unido, DA2 8DA
        • Darent Valley Hospital
      • Gillingham, Kent, Reino Unido, ME7 5NY
        • Medway Maritime Hospital
    • Lancashire
      • Preston, Lancashire, Reino Unido, PR2 9HT
        • Royal Preston Hospital
    • Leicestershire
      • Leicester, Leicestershire, Reino Unido, LE5 4PW
        • Leicester General Hospital
    • Middlesex
      • Harrow, Middlesex, Reino Unido, HA1 3UJ
        • Northwick Park Hospital
    • Oxfordshire
      • Headington, Oxfordshire, Reino Unido, OX3 7LE
        • Churchill Hospital
    • South Yorkshire
      • Sheffield, South Yorkshire, Reino Unido, S10 2JF
        • Royal Hallamshire Hospital
    • Suffolk
      • Ipswich, Suffolk, Reino Unido, IP4 5PD
        • Ipswich Hospital
    • Surrey
      • Croydon, Surrey, Reino Unido, CR7 7YE
        • Croydon University Hospital
      • Guildford, Surrey, Reino Unido, GU2 7XX
        • Royal Surrey County Hospital
    • Tyne and Wear
      • Newcastle upon Tyne, Tyne and Wear, Reino Unido, NE7 7DN
        • Freeman Hospital
    • West Midlands
      • Wolverhampton, West Midlands, Reino Unido, WV10 0QP
        • New Cross Hospital
    • West Sussex
      • Chichester, West Sussex, Reino Unido, PO19 6SE
        • St Richard's Hospital
      • Worthing, West Sussex, Reino Unido, BN11 2DH
        • Worthing Hospital
    • West Yorkshire
      • Wakefield, West Yorkshire, Reino Unido, WF1 4DG
        • Pinderfields General Hospital
    • Worcestershire
      • Kidderminster, Worcestershire, Reino Unido, DY11 6RJ
        • Kidderminster Hospital
      • Redditch, Worcestershire, Reino Unido, B98 7UB
        • Alexandra Hospital
      • Worcester, Worcestershire, Reino Unido, WR5 1DD
        • Worcester Royal Hospital
    • Yorkshire
      • Leeds, Yorkshire, Reino Unido, LS9 7TF
        • St James's University Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

16 años y mayores (Niño, Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Written informed consent
  • NMIBC recurrence following original diagnosis of low risk NMIBC (defined as Ta G1 or Ta G2 (Ta low grade) with a risk of recurrence score of ≤6 using EORTC risk tables
  • Histologically confirmed Transitional-cell carcinoma (TCC) at original diagnosis
  • Aged 16 or over
  • Satisfactory pre-treatment haematology values and serum creatinine < 1.5 x Upper Limit of Normal (ULN)
  • Negative pregnancy test for women of child-bearing potential

Exclusion Criteria:

  • Any history of: grade 3/high grade or ≥T1 transitional cell carcinoma, concomitant carcinoma in situ, more than 7 tumours at one diagnosis or more than 1 recurrence per year since initial diagnosis or in the past five years, whichever is shorter
  • Any history of histologically confirmed non-TCC bladder cancer
  • Trial entry recurrence identified within 11.5 months of the date of the original diagnosis
  • Any prior treatment of the trial entry recurrence (including biopsy)
  • Previous MMC chemotherapy other than a single instillation at diagnostic surgery
  • Known allergy to MMC
  • Carcinoma involving the prostatic urethra or upper urinary tract (participants should have had imaging of the upper urinary tract within 2 years prior to randomisation)
  • Known or suspected reduced bladder capacity (<100ml)
  • Significant bleeding disorder
  • Female patients who are breast-feeding or are of childbearing potential and unwilling or unable to use adequate non-hormonal contraception. Male patients should also use contraception if sexually active.
  • Active or intractable urinary tract infection
  • Urethral stricture or anything impeding the insertion of a catheter
  • Large narrow neck diverticula
  • Significant urinary incontinence
  • Any other conditions that in the Principal Investigator's opinion would contraindicate protocol treatment
  • Unable or unwilling to comply with study procedures or follow up schedule

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Chemoresection

4 once weekly outpatient intravesical instillations 40mg Mitomycin C

Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg MMC as outpatients.

Otros nombres:
  • CMM
Otro: Surgical Management

Surgical management according to local practice

Patients in this group should be treated according to local practice. Surgical interventions may include transurethral resection (TUR) or ablation.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Complete response rate with chemoresection
Periodo de tiempo: 3 months

Defined as an absence of any tumour following chemoresection and will be assessed visually at 3 month check cystoscopy by patients' urologists. A biopsy of the tumour bed would take place to confirm visual assessment of complete response.

3 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Treatment compliance in chemoresection group
Periodo de tiempo: Duration of treatment (3 weeks)

Patients who receive 4 MMC instillations with no more than 14 days between each instillation will be described as fully compliant.

Duration of treatment (3 weeks)
Salvage surgery rates
Periodo de tiempo: 3 years

Assessing trans-urethral resection and biopsy rates following initial treatment in both treatment groups

3 years
Progression-free survival
Periodo de tiempo: 3 years

Defined as time from randomisation to the first of muscle invasive bladder recurrence, recurrence in the pelvic nodes, distant metastatic recurrence or death from any cause.

3 years
Toxicity (NCI Common Toxicity Criteria for Adverse Effects (CTCAE) V4 and Clavien Dindo grade (in surgical group))
Periodo de tiempo: up to 12 months

Measuring side effects of both treatments using clinician reported toxicity scales

up to 12 months
European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) and Superficial Bladder Cancer (BLS24) questionnaire
Periodo de tiempo: up to 12 months

Assessing side effects and impact of both treatments on patient reported quality of life.

up to 12 months
Health service utilisation
Periodo de tiempo: up to 12 months

Assessed using prospective data collection of health resource usage.

up to 12 months
Recurrence free interval
Periodo de tiempo: up to 12 months

Time from end of treatment to first relapse, in patients confirmed recurrence free at 3 months

up to 12 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Hugh Mostafid, Royal Surrey County Hospital NHS Foundation Trust

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de octubre de 2014

Finalización primaria (Actual)

1 de enero de 2018

Finalización del estudio (Actual)

21 de febrero de 2022

Fechas de registro del estudio

Enviado por primera vez

19 de febrero de 2014

Primero enviado que cumplió con los criterios de control de calidad

21 de febrero de 2014

Publicado por primera vez (Estimado)

25 de febrero de 2014

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

9 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

4 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir